"MNGI Digestive Health (previously Minnesota Gastroenterology) specializes in the diagnosis and treatment of adults and children with GI disorders. Our board-certified gastroenterologists have expertise in virtually all types of digestive conditions, such as acid reflux disease, heartburn and swallowing disorders, Crohn's disease and ulcerative colitis, hepatitis and liver disease, biologics and infusion therapy, celiac disease, hemorrhoid banding and more."

During the past decade, Minnesota Gastroenterology, P.A. conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 30 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 17 clinical trials were completed. i.e. 283.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Minnesota Gastroenterology, P.A." #1 sponsor was "Gilead Sciences" with 11 trials, followed by "Shire" with 9 trials sponsored, "Bristol-Myers Squibb" with 4 trials sponsored, "Medtronic - MITG" with 4 trials sponsored and "Eli Lilly and Company" with 4 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Minnesota Gastroenterology, P.A." #1 collaborator was "Crohn's and Colitis Foundation" with 1 trials as a collaborator, "Dr. Naga Chalasani, MD, Indiana University" with 1 trials as a collaborator, "Dr. Stephen A. Harrison, MD, Brooke Army Medical Center" with 1 trials as a collaborator, "Elan Pharmaceuticals" with 1 trials as a collaborator and "Ethicon Endo-Surgery" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Minnesota Gastroenterology, P.A." are "Crohn's Disease" (13 trials), "Ulcerative Colitis" (8 trials), "Chronic Hepatitis C" (5 trials), "Eosinophilic Esophagitis" (3 trials) and "Eosinophilic Esophagitis (EoE)" (3 trials). Many other conditions were trialed in "Minnesota Gastroenterology, P.A." in a lesser frequency.

Most popular intervention types in "Minnesota Gastroenterology, P.A." are "Drug" (43 trials), "Other" (9 trials), "Biological" (4 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "RBV" (4 trials), "Mirikizumab" (3 trials), "SOF" (3 trials) and "placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Minnesota Gastroenterology, P.A." are 56 trials for "All" genders.

Currently, there are NaN active trials in "Minnesota Gastroenterology, P.A.". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 37 completed trials in Minnesota Gastroenterology, P.A., undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Minnesota Gastroenterology, P.A., 0 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".